Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Roxatidine Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxatidine Acetate SCHEMBL29389759 | 1.00 | HRH2 (0.98) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL1393 | 0.99 | HRH2 (1.00) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL29965995 | 0.99 | HRH2 (1.00) | HRH2HRH3 | |
| SCHEMBL11399763 | 0.99 | HRH2 (1.00) | HRH2HRH3 | |
| SCHEMBL11182082 | 0.98 | HRH2 (0.98) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL1650455 | 0.97 | HRH2 (0.96) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL9084471 | 0.97 | HRH2 (0.96) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL482841 | 0.95 | HRH2 (0.93) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL2322201 | 0.93 | HRH2 (0.89) | HRH2HRH3 | |
| SCHEMBL11179081 | 0.90 | HRH2 (0.83) | HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693469-B | Synthesis and refining method of roxatidine acetate hydrochloride | 四川汇宇制药股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2024221494-A1 | CATALYST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海凯赛生物技术股份有限公司 | 2024-10-31 | — | — | WO | claimed |
| CN-118847119-A | Catalyst and preparation method and application thereof | 上海凯赛生物技术股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118724839-A | Preparation method of high-purity roxatidine acetate hydrochloride | 天津力生制药股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240293329-A1 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | COSMAXPHARMA CO.,LTD. (KR) | 2024-09-05 | — | — | US | claimed |
| CN-221637787-U | Injection mixing device for roxatidine acetate hydrochloride for injection | 合肥昊益医药科技有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-221578892-U | Storage device for roxatidine acetate hydrochloride for injection | 合肥昊益医药科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-221295190-U | Transportation positioning device for roxatidine acetate hydrochloride for injection | 合肥昊益医药科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-117420232-A | Method for measuring content of roxatidine acetate hydrochloride for injection | 海南卫康制药(潜山)有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117180274-A | Roxatidine acetate composition for injection and preparation method thereof | 海南卫康制药(潜山)有限公司 | 2023-12-08 | — | — | CN | claimed |
| EP-1319399-A1 | MEDICINAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-18 | — | — | EP | claimed |
| US-6350468-B1 | ORALLY ADMINISTERING TO MAMMAL DOSAGE FORM COMPRISING INTERNAL CAPSULE COMPRISING ANTIBIOTIC PLACED INSIDE EXTERNAL CAPSULE COMPRISING SOLUBLE BISMUTH SALT AND SECOND ANTIBIOTIC; TRIPLE THERAPY AGAINST MICROORGANISM HELICOBACTER PYLORI | AXCAN PHARMA INC. (CA) | 2002-02-26 | — | — | US | claimed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-6287596-B1 | DRUG DELIVERY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-11 | — | — | US | claimed |
| EP-1037614-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | Axcan Pharma Inc. (CA) | 2000-09-27 | — | — | EP | claimed |
| WO-1999030693-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC. (CA) | 1999-06-24 | — | — | WO | claimed |
| EP-0922464-A1 | QUICKLY DISINTEGRABLE COMPRESSION-MOLDED MATERIALS AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-16 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |